newsfilter
← Latest News
GlobeNewswire·

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and